Sökning: onr:"swepub:oai:DiVA.org:uu-435149" >
The dapagliflozin a...
-
Wheeler, David C.UCL, Dept Renal Med, London, England.
(författare)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-08-30
-
OXFORD ENGLAND :Oxford University Press (OUP),2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-435149
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-435149URI
-
https://doi.org/10.1093/ndt/gfaa234DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Stefansson, Bergur, VAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
(författare)
-
Batiushin, MikhailRostov State Med Univ, Dept Nephrol, Rostov Na Donu, Russia.
(författare)
-
Bilchenko, OleksandrKharkiv Med Acad Postgrad Educ, Kharkiv, Ukraine.
(författare)
-
Cherney, David Z., IUniv Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.;Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada.
(författare)
-
Chertow, Glenn M.Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA.;Stanford Univ, Dept Med, Sch Med, Stanford, CA USA.
(författare)
-
Douthat, WalterHosp Privado Univ Cordoba, Dept Nephrol, Cordoba, Argentina.
(författare)
-
Dwyer, Jamie P.Vanderbilt Univ, Med Ctr, Nashville, TN USA.
(författare)
-
Escudero, ElizabethCayetano Heredia Univ, Hosp Arzobispo Loayza, Div Nephrol, Lima, Peru.
(författare)
-
Pecoits-Filho, RobertoPontificia Univ Catolica Parana, Sch Med, Curitiba, Parana, Brazil.;Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
(författare)
-
Furuland, HansUppsala universitet,Njurmedicin(Swepub:uu)hansfl
(författare)
-
Gorriz, Jose LuisUniv Valencia, Univ Clin Hosp, Dept Nephrol, INCLIVA, Valencia, Spain.
(författare)
-
Greene, TomUniv Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA.
(författare)
-
Haller, HermannHannover Med Sch, Hannover, Germany.
(författare)
-
Hou, Fan FanSouthern Med Univ, Natl Clin Res Ctr Kidney Dis, Dept Med, Div Nephrol, Guangzhou, Peoples R China.
(författare)
-
Kang, Shin-WookYonsei Univ, Dept Internal Med, Div Nephrol, Coll Med, Seoul, South Korea.
(författare)
-
Isidto, ReyHealthlink Med Dent Surg Clin & Diagnost Ctr, Iloilo, Philippines.
(författare)
-
Khullar, DineshMax Super Special Hosp, Dept Nephrol & Renal Transplant Med, New Delhi, India.
(författare)
-
Mark, Patrick B.Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
(författare)
-
McMurray, John J., VUniv Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
(författare)
-
Kashihara, NaokiKawasaki Med Sch, Dept Nephrol & Hypertens, Okayama, Japan.
(författare)
-
Nowicki, MichalMed Univ Lodz, Dept Nephrol Hypertens & Kidney Transplantat, Lodz, Poland.
(författare)
-
Persson, FrederikSteno Diabet Ctr Copenhagen, Gentofte, Denmark.
(författare)
-
Correa-Rotter, RicardoNatl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico.
(författare)
-
Rossing, PeterSteno Diabet Ctr Copenhagen, Gentofte, Denmark.;Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
(författare)
-
Toto, Robert D.UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA.
(författare)
-
Umanath, KausikHenry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA.;Wayne State Univ, Div Nephrol & Hypertens, Detroit, MI USA.
(författare)
-
Van Bui, PhamPham Ngoc Thach Med Univ, Ho Chi Minh City, Vietnam.
(författare)
-
Wittmann, IstvanUniv Pecs, Dept Med 2, Med Sch, Pecs, Hungary.;Univ Pecs, Nephrol Diabet Ctr, Med Sch, Pecs, Hungary.
(författare)
-
Lindberg, MagnusAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
(författare)
-
Sjostrom, C. DavidAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
(författare)
-
Langkilde, Anna MariaAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
(författare)
-
Heerspink, Hiddo J. L.Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
(författare)
-
UCL, Dept Renal Med, London, England.AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Nephrology, Dialysis and TransplantationOXFORD ENGLAND : Oxford University Press (OUP)35:10, s. 1700-17110931-05091460-2385
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Wheeler, David C ...
-
Stefansson, Berg ...
-
Batiushin, Mikha ...
-
Bilchenko, Oleks ...
-
Cherney, David Z ...
-
Chertow, Glenn M ...
-
visa fler...
-
Douthat, Walter
-
Dwyer, Jamie P.
-
Escudero, Elizab ...
-
Pecoits-Filho, R ...
-
Furuland, Hans
-
Gorriz, Jose Lui ...
-
Greene, Tom
-
Haller, Hermann
-
Hou, Fan Fan
-
Kang, Shin-Wook
-
Isidto, Rey
-
Khullar, Dinesh
-
Mark, Patrick B.
-
McMurray, John J ...
-
Kashihara, Naoki
-
Nowicki, Michal
-
Persson, Frederi ...
-
Correa-Rotter, R ...
-
Rossing, Peter
-
Toto, Robert D.
-
Umanath, Kausik
-
Van Bui, Pham
-
Wittmann, Istvan
-
Lindberg, Magnus
-
Sjostrom, C. Dav ...
-
Langkilde, Anna ...
-
Heerspink, Hiddo ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Nephrology, Dial ...
- Av lärosätet
-
Uppsala universitet